88 results
6-K
EX-99.2
CALT
Calliditas Therapeutics AB
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
’ business, operations, commercialization of TARPEYO and Kinpeygo, clinical trials, supply chain, strategy, goals and anticipated timelines
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
20 Dec 23
Current report (foreign)
5:13pm
, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in the section entitled “Risk
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
30 Nov 23
Current report (foreign)
4:05pm
, clinical trials (including as to the timing of the Company’s clinical trial of setanaxib in Alport syndrome), strategy, goals and anticipated
6-K
EX-99.1
9xqizl0osh 83
24 Nov 23
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy
4:05pm
6-K
EX-99.2
zfn0bae
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
9j1hhyhchapom6jh
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
r1eicej5rajff 7e
5 Oct 23
Current report (foreign)
4:05pm
6-K
EX-99.1
zrrue5ze7hlnostv
27 Sep 23
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
4:04pm
6-K
EX-99.1
pxrr81 0ocoixp43o
18 Aug 23
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
4:05pm
6-K
EX-99.2
uxylz8r9ugnm
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
6-K
EX-99.1
u6rr0nl28dje2rdrzej
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
6-K
EX-99.1
3vdj0p39993vmzf6nu
17 Jul 23
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
4:05pm
6-K
EX-99.1
ujadpv60ytlvkz yzv6y
21 Jun 23
Current report (foreign)
4:05pm
6-K
EX-99.2
m2rp6sjp
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.1
xdgrnbpa
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.2
1n8o4g4galnk1wgk5n6
28 Apr 23
Current report (foreign)
4:05pm